Discover
MLTX
MoonLake Immunotherapeutics
16.47
1 x 16.30
5 x 16.60
bid
ask
-
0.03
0.18%
200 @ 04:00 PM
16.50 +0.03 (0.18%)
| Ytd | 24.96% | |
| 1y | -69.99% |
16.30
day range
16.67
6.24
52 week range
61.99
| Open | 16.31 | Prev Close | 16.50 | Low | 16.30 | High | 16.67 | Mkt Cap | 1.39B |
| Vol | 930.41K | Avg Vol | 1.20M | EPS | -3.87 | P/E | -4.26 | Forward P/E | -4.93 |
| Beta | 1.07 | Short Ratio | 5.27 | Inst. Own | 80.27% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 18.91 | 200-d Avg | 16.53 | 1yr Est | 28.54 |
| Income Statement | |||
| Operating Expenses | 61.66M | ||
| Research and Development Expense | 50.22M | ||
| Selling, General and Administrative Expense | 11.44M | ||
| Operating Income | -61.66M | ||
| Interest Expense | 2.63M | ||
| Income Tax Expense | 90.00K | ||
| Net Income | -61.80M | ||
| Net Income Common Stock | -61.80M | ||
| Net Income Common Stock (USD) | -61.80M | ||
| Consolidated Income | -61.80M | ||
| Earnings per Basic Share | -0.84 | ||
| Earnings per Basic Share (USD) | -0.84 | ||
| Earnings per Diluted Share | -0.84 | ||
| Earning Before Interest & Taxes (EBIT) | -59.08M | ||
| Earning Before Interest & Taxes (USD) | -59.08M | ||
| Weighted Average Shares | 73.92M | ||
| Weighted Average Shares Diluted | 73.92M | ||
| Balance Sheet | |||
| Cash and Equivalents | 477.91M | ||
| Cash and Equivalents (USD) | 477.91M | ||
| Investments | 59.13M | ||
| Investments Current | 59.13M | ||
| Trade and Non-Trade Receivables | 6.56M | ||
| Current Assets | 570.04M | ||
| Property, Plant & Equipment Net | 2.57M | ||
| Total Assets | 573.95M | ||
| Debt Current | 1.25M | ||
| Total Debt | 101.53M | ||
| Current Liabilities | 45.39M | ||
| Debt Non-Current | 100.29M | ||
| Total Liabilities | 145.75M | ||
| Accumulated Retained Earnings (Deficit) | -594.42M | ||
| Accumulated Other Comprehensive Income | 630.00K | ||
| Shareholders Equity | 428.20M | ||
| Shareholders Equity (USD) | 428.20M | ||
| Assets Non-Current | 3.91M | ||
| Total Debt (USD) | 101.53M | ||
| Liabilities Non-Current | 100.36M | ||
| Trade and Non-Trade Payables | 17.04M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 896.00K | ||
| Net Cash Flow from Financing | 234.62M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 179.42M | ||
| Issuance (Purchase) of Equity Shares | 234.62M | ||
| Net Cash Flow from Investing | 322.00K | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 322.00K | ||
| Net Cash Flow from Operations | -55.56M | ||
| Effect of Exchange Rate Changes on Cash | 29.00K | ||
| Share Based Compensation | 2.55M | ||